检索结果-南通市图书馆

养阴解毒方联合安罗替尼治疗晚期非小细胞肺癌临床观察

在线全文

学校读者我要写书评

暂无评论

辽宁中医药大学学报 2024年第1期26卷 101-105页

作者：钟妍顾爱琴孙建立上海市长宁区天山中医医院上海200050 上海市胸科医院上海200032 上海中医药大学附属龙华医院上海200032

目的研究养阴解毒方联合安罗替尼治疗晚期非小细胞癌(NSCLC)患者,探索养阴解毒方联合安罗替尼在晚期NSCLC人群中的有效性和安全性。方法采用前瞻性队列研究方法录入116例患者,分为观察组(养阴解毒方联合安罗替尼)58例、对照组(单纯安... 详细信息

目的研究养阴解毒方联合安罗替尼治疗晚期非小细胞癌(NSCLC)患者,探索养阴解毒方联合安罗替尼在晚期NSCLC人群中的有效性和安全性。方法采用前瞻性队列研究方法录入116例患者,分为观察组(养阴解毒方联合安罗替尼)58例、对照组(单纯安罗替尼)58例,记录患者的一般资料,观察两组患者的PFS、实体瘤客观疗效、中医证候积分、卡氏生存质量评分(KPS)、不良反应等,使用SPSS 22.0统计软件对研究数据进行统计学分析。结果观察组的无进展生存期(PFS)为7.6个月,对照组PFS为5.4个月,差异无统计学意义(P>0.05);观察组客观缓解率(ORR)为6.9%,疾病控制率(DCR)为89.7%,对照组ORR为5.2%,DCR为84.5%,组间比较无统计学意义(P>0.05);在改善痰中带血、神疲乏力、自汗盗汗、口干咽燥等中医证候方面,观察组有效率更高,差异有统计学意义(P0.05)。结论养阴解毒方联合安罗替尼治疗方案相较于单纯安罗替尼治疗方案,可延长肿瘤患者PFS,有效改善晚期NSCLC患者临床症状,降低不良反应发生率,并提高患者生存质量。

关键词：养阴解毒方安罗替尼晚期非小细胞肺癌

Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer

同方期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2013年第1期25卷 90-94页

作者： aiqin gu Chunlei Shi Liwen Xiong Tianqing Chu Jun Pei Baohui Han Department of pulmonary medicine Shanghai Chest Hospital Shanghai Jiao Tong University

Objective： To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer （NSCLC）. Methods： A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until disease progression or development of unacceptable toxicity. Results： A total of 89 patients were assessable. In patients treated with icotinib, the overall response rate （RR） was 36.0% （32/89）, and the disease control rate （DCR） was 69.7% （62/89）. RR and DCR were significantly improved in patients with adenocarcinoma versus non-adenocarcinoma （P〈0.05）. The symptom improvement rate was 57.3% （51/89）, and the main symptoms improved were cough, pain, chest distress, dyspnea, and Eastern Cooperative Oncology Group performance status. The main toxic effects were rash [30/89 （33.7%）] and diarrhea [15/89 （16.9%）]. The level of toxicity was typically low. Conclusions： The use of icofinib hydrochloride in the treatment of advanced NSCLC is efficacious and safe, and its toxic effects are tolerable.

关键词： Icotinib non-small cell lung cancer (NSCLC) targeted therapy

扶正方药治疗三线及以上晚期非小细胞肺癌临床疗效及对血清可溶性免疫检查点表达的影响

在线全文

学校读者我要写书评

暂无评论

上海中医药杂志 2024年第4期58卷 72-78页

作者：刘芳芳蔡雨晴姜怡顾爱琴刘苓霜上海中医药大学附属龙华医院上海200032 上海市胸科医院上海200030

目的观察扶正方药治疗三线及以上晚期非小细胞肺癌(NSCLC)患者的疗效及对血清可溶性免疫检查点表达的影响。方法根据治疗情况将211例三线及以上晚期NSCLC患者分为暴露组(106例)、非暴露组(105例),非暴露组给予标准西医治疗方案,暴露组... 详细信息

目的观察扶正方药治疗三线及以上晚期非小细胞肺癌(NSCLC)患者的疗效及对血清可溶性免疫检查点表达的影响。方法根据治疗情况将211例三线及以上晚期NSCLC患者分为暴露组(106例)、非暴露组(105例),非暴露组给予标准西医治疗方案,暴露组在标准西医治疗方案的基础上加用中医扶正方药。观察无进展生存期(PFS),绘制Kaplan-Meier生存曲线,对临床因素及预后指标进行Cox多因素分析;治疗4个周期后计算疾病控制率,比较生活质量量表[癌症患者生活质量核心问卷量表(QLQ-C30)、肺癌特异性量表(QLQ-LC13)]评分、血清可溶性免疫检查点[包括可溶性CD137(sCD137)、可溶性程序性细胞死亡配体1(sPD-L1)、可溶性程序性细胞死亡配体2(sPD-L2)、可溶性程序性死亡分子-1(sPD-1)、可溶性淋巴细胞激活基因-3蛋白(sLAG-3)、可溶性半乳糖凝集素-9(sGal-9)等]表达水平的变化情况。结果①暴露组脱落2例、非暴露组脱落1例,最终完成试验者208例,暴露组、非暴露组各104例。②暴露组、非暴露组的中位PFS分别为7.5个月、6.3个月,暴露组PFS长于非暴露组(χ^(2)=4.656,P0.05)。④治疗前后组内比较,暴露组QLQ-C30量表中躯体功能、情绪功能、认知功能和总健康状况、疲倦、疼痛、气促、失眠、食欲、便秘、腹泻评分差异有统计学意义(P<0.05),QLQ-LC13量表中气促、咳嗽、口腔溃疡、其他部位痛评分降低(P<0.05);非暴露组QLQ-C30量表中躯体功能、社会功能、疼痛、气促、便秘、腹泻评分差异有统计学意义(P<0.05),QLQ-LC13量表中气促、咳嗽评分降低(P<0.05),其他部位痛评分升高(P<0.05)。组间治疗后比较,QLQ-C30量表中躯体功能、总健康状况、疲倦、疼痛、气促、食欲、便秘评分差异有统计学意义(P<0.05),QLQ-LC13量表中气促、咳嗽、口腔溃疡及其他部位痛评分差异有统计学意义(P<0.05)。⑤治疗前后组内比较,暴露组血清sPD-L1、sPD-L2水平降低,sPD-1、sGal-9水平升高(P<0.05);组间治疗后比较,sCD137、sPD-L1、sPD-L2、sLAG-3水平差异有统计学意义(P<0.05)。结论与单纯使用西医治疗相比,加用扶正方药治疗三线及以上晚期NSCLC患者具有延长PFS、改善生活质量、调节免疫微环境等作用。

关键词：非小细胞肺癌肿瘤生存期中药中西医结合疗法免疫检查点临床试验

The Infection of Healthcare Workers and the Reinfection of Patients by Omicron Variant—Jiangsu Province,China,December 2022 to January 2023

在线全文

学校读者我要写书评

暂无评论

China CDC weekly 2023年第18期5卷 402-406页

作者： Chuanmeng Zhang Ting guo Lei Zhang aiqin gu Jun Ye Mei Lin Ming Chu Fengcai Zhu Li Zhu The Affiliated Taizhou People’s Hospital of Nanjing Medical University Taizhou CityJiangsu ProvinceChina Nanjing University of Chinese Medicine Nanjing CityJiangsu ProvinceChina Jiangsu Provincial Center for Disease Control and Prevention Nanjing CityJiangsu ProvinceChina Nanjing Medical University Nanjing CityJiangsu ProvinceChina

Summary What is already known about this topic?Healthcare workers(HCWs)and previously infected patients(PIPs)may experience a wave of epidemic following the modification of the country’s coronavirus disease(COVID)-zero policy in *** is added by this report?As of early January 2023,the initial wave of the COVID-19 pandemic among HCWs had effectively subsided,with no statistically significant differences observed in infection rates compared to those of their *** proportion of reinfections among PIPs was relatively low,particularly in those with recent *** are the implications for public health practice?Medical and health services have resumed normal *** patients who have recently experienced severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infections,appropriate relaxation of policies may be considered.

关键词： sided operations resume

Mutational Analysis of OCT4+ and OCT4− Circulating Tumour Cells by Single Cell Whole Exome Sequencing in Stage I Non-Small Cell Lung Cancer Patients

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Shanghai Jiaotong university(Science) 2021年第1期26卷 40-46页

作者： YAN Bo FU Shijie CHANG Yuanyuan gu aiqin DONG Qianggang LI Rong Department of Pulmonary Medicine Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China Department of Thoracic Surgery Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China Cancer Stem Cell Research Group Shanghai Jiao Tong University Cancer InstituteShanghai 200032China

Circulating tumour cells(CTCs)were enriched in the peripheral blood of four patients with Stage I non-small cell lung cancer(NSCLC).Octamer-binding transcription factor-4 positive(OCT4+)and negative(OCT4−)CTCs were identified and captured by interphase fluorescence in situ hybridisation(iFISH).Single cell whole exome sequencing(WES)was performed and the corresponding bioinformatics data were ***4+cells were successfully detected in peripheral blood collected from all four Stage I lung cancer ***,the tumour mutational burden(TMB)values observed for OCT4+samples from the same patients were slightly smaller than those of the OCT4−samples;the difference was not statistically significant(P>0.05).Thirteen and six characteristic mutations were found in negative samples and positive samples,*** findings indicate that this methodology provides a potential diagnostic index for the early detection of NSCLC.

关键词： non-small cell lung cancer(NSCLC) octamer-binding transcription factor-4(OCT4) circulating tumour cells(CTCs) whole exome sequencing(WES)

The expressions and clinical significance of P53, C-erbB-2 and VEGF in non-small cell lung cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical Oncology 2008年第2期7卷 78-80页

作者： aiqin gu Yu Xin Gang Chen Baohui Han Hao Ji Bo Yan Department of Pneumology Shanghai Chest Hospital of Jiaotong University Shanghai 200030 China Department of Pathology Shanghai Chest Hospital of Jiaotong University Shanghai 200030 China

Objective： To investigate the expressions and the clinical significance of P53, C-erbB-2 and vascular endothelial growth factor （VEGF） in non-small cell lung cancer （NSCLC）. Methods： 121 specimens of NSCLC were examined for P53, C-erbB-2 and VEGF by immunohistochemical staining. Results： The positive rates of P53, C-erbB-2 and VEGF in the carcinomatous tissue were 43%, 39% and 31% respectively. P53 gene protein expression in lung cancer was significantly related to histological type and P-TNM staging of lung cancer patients （P 〈 0.05）, and was not associated with the sex, age, the size of primary cancer, lymph node metastasis and cell differentiation （P 〉 0.05）. C-erbB-2 gene protein expression in lung cancer was closely related to histological type and cell differentiation （P 〈 0.05）, and was not associated with the sex, age, the size of primary cancer, lymph node metastasis and P-TNM staging of lung cancer patients （P 〉 0.05）. VEGF in lung cancer was only closely related to cell differentiation （P 〈 0.05）, and was not associated with the sex, age, the size of pdmary cancer, lymph node metastasis, histological type and P-TNM staging of lung cancer patients （P 〉 0.05）. Conclusion： It is possible for P53, C-erbB-2 and VEGF to play an important role in the oncogenesis and development of non-small cell lung cancer.

关键词： non-small cell lung cancer (NSCLC) P53 C-erbB-2 vascular endothelial growth factor (VEGF)

A Clinical Study:ERCC1 Protein as a guide for Individualized Therapy of Late-Stage Advanced Non-Small Cell Lung Cancer

在线全文

学校读者我要写书评

暂无评论

A Clinical Study:ERCC1 Protein as a Guide for Individualized...

正常儿童血清中邻苯二甲酸二丁酯和邻苯二甲酸-2-乙基己酯水平的测定

中华医学会呼吸病学年会——2013（第十四次全国呼吸病学学术会议）

作者： Zhiqiang Gao Baohui Han Jie Shen aiqin gu Liyan Jiang 上海市胸科医院

Excision repair cross-complementation group 1(ERCC 1) protein has been associated with cisplatin resistance .The objective of this study was to investigate the corre lation between the ERCC1 protein level and the therap eutic effect of individualized therapy on advanced non-small cell lung cancer.A total of 190 advanced non-small cell lung cancer(NSC LC) patients were included in this *** patients were randomized into either the individualized therapy

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

卫生研究 2010年第4期39卷 501-503页

作者：乔丽丽蔡德培申建伟顾爱琴上海市松江区中心医院儿科上海201600 复旦大学附属儿科医院

目的检测正常儿童血清中邻苯二甲酸二丁酯(DBP)和邻苯二甲酸-2-乙基己酯(DEHP)水平。方法选择上海市正常儿童作为研究对象,用气相色谱检测其血清中DBP、DEHP含量,作正常儿童血清DBP、DEHP浓度分布,以及DBP、DEHP不同年龄和性别水平分析... 详细信息

目的检测正常儿童血清中邻苯二甲酸二丁酯(DBP)和邻苯二甲酸-2-乙基己酯(DEHP)水平。方法选择上海市正常儿童作为研究对象,用气相色谱检测其血清中DBP、DEHP含量,作正常儿童血清DBP、DEHP浓度分布,以及DBP、DEHP不同年龄和性别水平分析。结果 310例血样中,110例可检出DBP,118可检出DEHP,全部样品中DBP的浓度范围为未检出～0.98ng/ml,P75为0.68ng/ml,95%上限为0.75ng/ml,男女检出率无差别,检出率在不同年龄组间存在差别。全部样品中DEHP的浓度范围为未检出～0.94ng/ml,P75为0.67ng/ml,95%上限为0.74ng/ml,男女检出率无差别,检出率在不同年龄组间存在差别,婴儿组的检出率明显低于其他组。结论正常儿童的血清DBP、DEHP浓度较低,DBP低于0.75ng/ml,DEHP低于0.74ng/ml。

关键词：邻苯二甲酸酯类邻苯二甲酸二丁酯邻苯二甲酸-2-乙基己酯气相色谱法环境污染

ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer

在线全文

学校读者我要写书评

暂无评论

ERCC1 protein as a guide for individualized therapy of late-...